Neovasc

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.

VANCOUVER, Nov.  19, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that its transfemoral trans-septal ("TF/TS") Tiara™ (“Tiara”) System was featured today in a tutorial session at the PCR London Valves 2019 meeting, which is taking place November 17-19 in London.

Neovasc Tiara™ Progress Highlighted at PCR London Valves 2019

VANCOUVER and MAINZ, Germany, Nov.  12, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a new milestone has been reached in Germany with the 200th patient implant of the Neovasc Reducer™ (the "Reducer").

Neovasc Reducer™ Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany

Neovasc, Inc. (NVCN) CEO Fred Colen on Q3 2019 Results - Earnings Call Transcript

Neovasc Announces Third Quarter 2019 Financial Results

Vancouver, Nov.  07, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the appointment of Bill Little as the Company’s Chief Operating Officer, reporting directly to the CEO. Mr. Little is an accomplished global marketing executive with more than two decades of experience in the medical device and technology spaces, specializing in interventional cardiology and structural heart disease.

Neovasc Appoints Cardiovascular Industry Veteran Bill Little as Chief Operating Officer

VANCOUVER, BC, Nov.  06, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Neovasc, Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred Colen, CEO of Neovasc, will be participating in two institutional investor conferences in November.  

Neovasc to Participate in Stifel 2019 Healthcare Conference and Cannacord Genuity 13th Annual MedTech & Diagnostics Forum

Vancouver, BC, Nov.  05, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the company will be providing an update on its Transfemoral Trans-septal ("TF/TS") Tiara System at the PCR London Valves 2019 meeting, which takes place November 17-19 in London.

Neovasc to Provide Update on TF/TS Tiara Program at PCR Valves 2019

VANCOUVER, Nov.  01, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it intends to submit a full Premarket Approval application (“PMA”) to the U.S. Food and Drug Administration (“FDA”) for its Neovasc Reducer™ (“Reducer”) medical device for the treatment of refractory angina before the end of 2019. 

Neovasc to Submit Full PMA Application for Neovasc Reducer™ in 2019

Neovasc (NVCN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neovasc (NVCN) Expected to Beat Earnings Estimates: Should You Buy?

VANCOUVER and MILAN, Oct.  22, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (“Reducer”) was featured in multiple presentations during the symposium “A Proven Evidence-based therapy when Angina Persists”, held this month at the National Congress of the Italian Society of Interventional Cardiology (GISE) in Milan, Italy.

Neovasc Reducer™ for Treatment of Refractory Angina Featured in Sponsored Session at the 40th Annual National Congress of the Italian Society of Interventional Cardiology

Company Ramps Up Commercialization of Neovasc Reducer™ and Development of Tiara™ Product Platforms, Primes for Pivotal Growth Period

Neovasc Retains Westwicke, ICR for Integrated Communications Counsel

VANCOUVER, Oct.  15, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Neovasc, Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the United States Patent and Trademark Office ( USPTO ) has issued US Patent No. 10,433,952, titled: “PROSTHETIC VALVE FOR AVOIDING OBSTRUCTION OF OUTFLOW”.

Neovasc Announces Notice of US Patent Granted for Tiara™ Transcatheter Device for Treatment of Severe Mitral Regurgitation

Announcement Made at European Society of Cardiology Congress 2019 in Paris, France Announcement Made at European Society of Cardiology Congress 2019 in Paris, France

The European Society of Cardiology Includes Neovasc Reducer™ for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes

Neovasc's (NVCN) CEO Fred Colen on Q2 2019 Results - Earnings Call Transcript

Shares of the Canadian medical device maker Neovasc Inc were rallying Tuesday following the circulation of a document with a patent abstract it filed with the U.S. Patent and Trademark Office.

Penny Stock Neovasc Rallies On Patent Abstract Filing

Neovasc Inc. (NVCN) CEO Fred Colen on Q1 2019 Results - Earnings Call Transcript

Neovasc Inc. (NVCN) CEO Fredericus Colen on Q4 2018 Results - Earnings Call Transcript

News for Neovasc Stock (NVCN)